Hypercholesterolemia — Efficacy of Lapaquistat Acetate and Simvastatin in Subjects With Primary Dyslipidemia.
Citation(s)
A Placebo-controlled, Double-blind, Randomized Study to Evaluate the Efficacy and Safety of TAK-475 50 mg and 100 mg Versus Placebo, When Co-administered With Simvastatin 20 mg or 40 mg in Subjects With Primary Dyslipidemia.